Guggenheim Reiterates Buy on Insmed, Maintains $207 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.9%

Neg 0% Neu 89.9% Pos 0%

Guggenheim analyst Vamil Divan reiterates Insmed (NASDAQ:INSM) with a Buy and maintains $207 price target.

Comments

No comments yet. Be the first!